In Celexir’s specialized portfolio, Teriparatide (PTH 1–34) is positioned for patients who need active bone formation—advanced osteoporosis, very-high fracture risk, or post-fracture rebuild. Clinically, it’s used to stimulate new trabecular bone while you address upstream drivers like vitamin D/calcium sufficiency, fall risk, and metabolic health.
How it works: Teriparatide is a recombinant fragment of parathyroid hormone that activates osteoblasts, increases bone mineral density, and reduces fracture risk by promoting remodeling and calcium retention. Landmark trials show decreased vertebral and non-vertebral fractures and superior BMD gains vs. some antiresorptives in high-risk cohorts.
Regulatory & evidence context: Teriparatide is FDA-approved for osteoporosis in patients at high fracture risk. The prior boxed warning about osteosarcoma and the strict lifetime 24-month limit were removed from the U.S. label; current labeling advises that use beyond 2 years should be considered only if the patient remains or returns to very high risk—a clinical judgement call supported by modern guidelines for very-high-risk cases.
Celexir delivery & specs: Ready-to-use prefilled pen or lyophilized vial; typical catalog protocol 20 mcg SC daily(historically up to 24 months), >98% purity (GMP-verified), 2–8 °C storage, and full CoA/protocol support for clean, repeatable clinic workflows. Integrate Teriparatide within a comprehensive plan (adequate calcium/vitamin D, antiresorptive sequence after anabolism, balance training), tracking BMD and fracture outcomes.